Investor Overview
Corporate Profile
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule, oligomer antagonists for age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).
Press Releases
November 13, 2024
Events
November 14, 2024 ET
October 30, 2024 ET
October 29, 2024 - November 1, 2024